Last $0.85 USD
Change Today -0.02 / -2.30%
Volume 6.0K
ENUM On Other Exchanges
Symbol
Exchange
OTC BB
As of 8:10 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

enumeral biomedical holdings (ENUM) Key Developments

Enumeral Biomedical Holdings, Inc. Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 12:00 PM

Enumeral Biomedical Holdings, Inc. Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 12:00 PM. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States.

Enumeral Biomedical Holdings, Inc. and Memorial Sloan Kettering Cancer Center to Research Cancer Immunology with Advanced Prototype System for Human Tissue Immuno-Oncology Profiling

Enumeral Biomedical Holdings, Inc. announced that the company signed an agreement with Memorial Sloan Kettering Cancer Center as part of Enumeral’s Phase II Small Business Innovation Research contract with the National Cancer Institute. Enumeral is developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which will be deployed at MSK in the laboratory of Jedd D. Wolchok, M.D., Ph.D., Chief of Melanoma and Immunotherapeutics Service, Lloyd J. Old/Ludwig Chair in Clinical Investigation Department of Medicine and Ludwig Center, at Memorial Sloan Kettering Cancer Center. Dr. Wolchok played a critical role in the clinical development of ipilimumab and nivolumab, immunotherapies which represent a transformational advancement in the treatment of cancer. Enumeral’s Phase II program is focused on applying its human-driven immune profiling platform to small volume clinical specimens such as core biopsy or fine needle aspirates, which often contain limited numbers of cells and can be challenging to analyze with conventional technologies. Enumeral’s human-driven immune profiling platform has the ability to determine cellular function in an unbiased fashion, allowing analysis of rare immune cells associated with disease or drug response in even the smallest clinical samples. Studying rare cells obtained directly from human patients for their functional responses can potentially lead to identification of those patients responsive to a therapy, while elucidating the underlying cellular basis for such a response, which may ultimately guide development of more precisely targeted immunotherapies. Enumeral’s collaboration with MSK is supported by a Phase II SBIR contract from the NCI for $999,967 over two years. The NCI is funding the entirety of the program, which complements Enumeral’s other internal research and development efforts. Enumeral demonstrated proof of concept in this area under a Phase I contract in 2012 and 2013.

Enumeral Biomedical Holdings, Inc. Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-18-2015 through Jan-21-2015

Enumeral Biomedical Holdings, Inc. Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-18-2015 through Jan-21-2015. Venue: Club Med, Sandpiper Bay, Florida, United States. Presentation Date & Speakers: Jan-19-2015, Arthur Tinkelenberg, Co-Founder, Chief Executive Officer, President and Director.

Enumeral Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Enumeral Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Enumeral Biomedical Holdings, Inc. and Merck Sharp & Dohme Corp. Form Collaboration for Predicting Clinical Drug Response with Human-Driven Immune Profiling Platform

Enumeral Biomedical Holdings, Inc. announced that it has signed an oncology-focused collaborative study agreement with Merck Sharp & Dohme Corp. The collaborators will use Enumeral's human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck. Enumeral's human-driven immune profiling platform may increase the probability of finding rare immune cells associated with disease or drug response through improved efficiency and sensitivity. Studying rare cells obtained directly from human patients for their functional responses can potentially lead to identification of those patients responsive to a therapy, while elucidating the underlying cellular basis for such a response. Under the terms of the agreement, Enumeral will receive R&D funding and is eligible to receive undisclosed future payments if certain goals are achieved. Merck has exclusive rights to data related to its proprietary compounds that are generated from the studies.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENUM:US $0.85 USD -0.02

ENUM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ENUM.
View Industry Companies
 

Industry Analysis

ENUM

Industry Average

Valuation ENUM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 154.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 125.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENUMERAL BIOMEDICAL HOLDINGS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.